Reyataz(atazanavir)
Evotaz, Reyataz (atazanavir) is a small molecule pharmaceutical. Atazanavir was first approved as Reyataz on 2003-06-20. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Reyataz (generic drugs available since 2014-04-22)
CombinationsEvotaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atazanavir sulfate
Atazanavir sulfate
+
Cobicistat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EVOTAZ | Bristol Myers Squibb | N-206353 RX | 2015-01-29 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
Agency Specific
FDA
EMA
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE08: Atazanavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR15: Atazanavir and cobicistat
— J05AR23: Atazanavir and ritonavir
HCPCS
No data
Clinical
Clinical Trials
153 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 19 | 15 | 22 | 28 | 11 | 93 |
| Hiv | D006678 | O98.7 | 5 | 3 | 6 | 8 | 5 | 26 | |
| Healthy volunteers/patients | — | 9 | — | — | 1 | — | 10 | ||
| Infections | D007239 | EFO_0000544 | — | 2 | 2 | 2 | — | 6 | |
| Hepatitis c | D006526 | B19.2 | 1 | — | — | 2 | — | 3 | |
| Hiv-1 | D015497 | 2 | — | — | 1 | — | 3 | ||
| Drug interactions | D004347 | — | — | — | 1 | 1 | 2 | ||
| Lipodystrophy | D008060 | E88.1 | — | — | — | 1 | 1 | 2 | |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | 1 | — | 1 | |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 2 | 1 | — | — | 2 | |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | 2 | — | — | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | — | 1 |
| Sars-cov-2 | D000086402 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | — | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ATAZANAVIR |
| INN | atazanavir |
| Description | Atazanavir is a heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV). It has a role as an antiviral drug and a HIV protease inhibitor. |
| Classification | Small molecule |
| Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C |
Identifiers
| PDB | — |
| CAS-ID | 198904-31-3 |
| RxCUI | 343047 |
| ChEMBL ID | CHEMBL1163 |
| ChEBI ID | 37924 |
| PubChem CID | 148192 |
| DrugBank | DB01072 |
| UNII ID | QZU4H47A3S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Reyataz - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,978 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
73 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more